Skip to main content

Polaryx Therapeutics, Inc.

Data quality: 83%
PLYX
NASDAQ Manufacturing Chemicals
$5.68
▼ $0.08 (-1.39%)
Mkt Cap: 265.27 M
Price
$5.84
Mkt Cap
265.27 M
Day Range
52-Week Range
Volume
Open —
50D / 200D Avg
50D / 200D Avg

Quick Summary

Key Takeaways

Negative free cash flow of -3.94 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-196.82%
Below sector avg (-54.44%)
ROIC-135.35%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio8.55
Interest CoverageN/A

Valuation

PE (TTM)
-29.52
Below sector avg (-1.49)
P/B Ratio58.11
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -29.5 -1.5
P/B 58.1 1.6
ROE % -196.8 -54.4
Net Margin % -41.5
Rev Growth 5Y % 1.9
D/E 0.3

Analyst Price Target

1 analyst
Strong Buy
Current
$5.68
+76.1%
Target
$10.00
$10.00
$10.00
$10.00
Forecast
Forward EPS -$0.28
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.28
-$0.28 – -$0.28
0.0 1
FY2026 -$0.12
-$0.12 – -$0.12
0.0 1

Earnings Surprises

Last 1 quarter
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.02 -$0.16 -700.0%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -8.99 M
ROE -196.82% ROA -173.79%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3.94 M
ROIC -135.35% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8.55
Interest Coverage N/A Asset Turnover N/A
Working Capital 4.57 M Tangible Book Value 4.57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -29.52 Forward P/E N/A
P/B Ratio 58.11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1.49%
Market Cap 265.27 M Enterprise Value 260.12 M
Per Share
EPS (Diluted TTM) -0.20 Revenue / Share N/A
FCF / Share -0.09 OCF / Share -0.09
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 43.90%
SBC-Adj. FCF -8.67 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue
Net Income -8.99 M
EPS (Diluted) -0.20
Gross Profit
Operating Income -7.82 M
EBITDA
R&D Expenses 6.27 M
SG&A Expenses
D&A
Interest Expense
Income Tax

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 5.17 M
Total Liabilities 605,000.0
Shareholders' Equity 4.57 M
Total Debt
Cash & Equivalents 5.14 M
Current Assets 5.17 M
Current Liabilities 605,000.0